Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02117336
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dartmouth-Hitchcock Norris Cotton Cancer Centre, Lebanon, New Hampshire, United States
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 100
- Registration Number
- NCT01910571
- Locations
- 🇺🇸
Facility: Profil® Institute for Clinical Research, Inc., Chula Vista, California, United States
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
- Conditions
- Radiation Induced Mucositis in Head and Neck Cancer
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 73
- Registration Number
- NCT01903018
- Locations
- 🇮🇳
Sri Venkateshwara Hospitals, Bangalore, Karnataka, India
🇮🇳Meenakshi Mission Hosp. & Res. Centre, Madurai, Tamil Nadu, India
🇮🇳Tata Memorial Hospital, Mumbai, Maharashtra, India
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 96
- Registration Number
- NCT01874366
- Locations
- 🇺🇸
Phase I clinic: MRA Clinical Research, Miami, Florida, United States
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- Conditions
- Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 100
- Registration Number
- NCT01841463
- Locations
- 🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸UCSF Medical Center at Mount Zion, South San Francisco, California, United States
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: PL225B
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 70
- Registration Number
- NCT01779336
- Locations
- 🇮🇳
Central India Cancer Research Institute, Nagpur, Maharashtra, India
🇮🇳Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 32
- Registration Number
- NCT01764425
- Locations
- 🇮🇳
Veeda Clinical Research, Ahmedabad, Gujarat, India
🇮🇳Piramal Clinical Research, Hyderabad, Andhra Pradesh, India
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 60
- Registration Number
- NCT01762410
- Locations
- 🇮🇳
Medanta Duke Research Institute (MDRI), Gurgaon, Haryana, India
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇮🇳Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01674348
- Locations
- 🇨🇦
LMC Endocrinolgy Centres Ltd, Toronto, Ontario, Canada
A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 298
- Registration Number
- NCT01373567
- Locations
- 🇮🇳
Renova Skin & Laser Clinic,Sector 9, Shopping Centre,Opposite Meera Marg, Madhyam Marg, Jaipur, Rajasthan, India
🇮🇳D.Y.Patil Medical college and Hospital, Dept. of Dermatology & STD,Sector-5, Nerul, Navi Mumbai, India
🇮🇳Skin & Laser Center,F-12/10 Krishna Nagar,, New Delhi, India